NEET UG 2026 is expected to witness intense competition, making NCERT-based preparation more crucial than ever for aspirants aiming for top medical colleges. Since the Biology section carries 90 ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

Immunotherapy has revolutionized cancer care by training the immune system to detect and destroy tumors. For many patients, ...

Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across ...

Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling molecules in autoimmune, graft rejection, and oncology UTRECHT, the Netherlands - 4 December 2025 (08:30 CET). Laigo ...

Global biopharma leader CSL today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® ...

Seaport Therapeutics to present at 2025 RBC Capital Markets Healthcare Private Company Conference and participate in ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

As researchers delve deeper into the science of the oral microbiome, preventive dental care is being redefined.

Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo ...

Structure Therapeutics has reported positive topline results from the ACCESS clinical programme for its investigational oral ...

Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients80% CR and ...